Search Results - "DANG, Nam H"

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL by Goy, Andre, Ramchandren, Radhakrishnan, Ghosh, Nilanjan, Munoz, Javier, Morgan, David S., Dang, Nam H., Knapp, Mark, Delioukina, Maria, Kingsley, Edwin, Ping, Jerry, Beaupre, Darrin M., Neuenburg, Jutta K., Ruan, Jia

“…The outcome of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is poor, particularly in patients ineligible for stem cell…”
Get full text

Involvement of activation induced cytidine deaminase in malignant B-cells expressing two distinct M-components as an etiology of biclonal gammopathy by Kikuchi, Shohei, Wada, Akinori, Kamihara, Yusuke, Nabe, Yoshimi, Minemura, Tomoki, Murakami, Jun, Dang, Nam H., Sato, Tsutomu

“…Biclonal gammopathy (BG) is a rare phenomenon in which 2 M proteins are detected in the same patient, with 2 major hypotheses regarding its etiology. One…”
Get full text

Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody by Ohnuma, Kei, Haagmans, Bart L, Hatano, Ryo, Raj, V Stalin, Mou, Huihui, Iwata, Satoshi, Dang, Nam H, Bosch, Berend Jan, Morimoto, Chikao

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab by FAYAD, Luis, OFFNER, Fritz, COIFFIER, Bertrand, CZUCZMAN, Myron, GINE, Eva, DURRANT, Simon, KNEISSL, Michelle, LUU, Kenneth T, HUA, Steven Y, BONI, Joseph, VANDENDRIES, Erik, DANG, Nam H, SMITH, Mitchell R, VERHOEF, Gregor, JOHNSON, Peter, KAUFMAN, Jonathan L, ROHATINER, Ama, ADVANI, Anjali, FORAN, James, HESS, Georg

“…Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent…”
Get full text

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers by Angevin, Eric, Isambert, Nicolas, Trillet-Lenoir, Véronique, You, Benoit, Alexandre, Jérôme, Zalcman, Gérard, Vielh, Philippe, Farace, Françoise, Valleix, Fanny, Podoll, Thomas, Kuramochi, Yu, Miyashita, Itaru, Hosono, Osamu, Dang, Nam H, Ohnuma, Kei, Yamada, Taketo, Kaneko, Yutaro, Morimoto, Chikao

“…Background: YS110 is a humanised IgG1 monoclonal antibody with high affinity to the CD26 antigen. YS110 demonstrated preclinical anti-tumour effects without…”
Get full text

Effective Dose Reduction to Cardiac Structures Using Protons Compared With 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma by Hoppe, Bradford S., M.D., M.P.H, Flampouri, Stella, Ph.D, Su, Zhong, Ph.D, Latif, Naeem, M.D, Dang, Nam H., M.D., Ph.D, Lynch, James, M.D, Joyce, Michael, M.D, Sandler, Eric, M.D, Li, Zuofeng, Ph.D, Mendenhall, Nancy P., M.D

“…Purpose We investigated the dosimetric impact of proton therapy (PT) on various cardiac subunits in patients with Hodgkin lymphoma (HL). Methods and Materials…”
Get full text

A Novel Mechanism for Bone Loss: Platelet Count Negatively Correlates with Bone Mineral Density via Megakaryocyte-Derived RANKL by Kikuchi, Shohei, Wada, Akinori, Kamihara, Yusuke, Yamamoto, Imari, Kirigaya, Daiki, Kunimoto, Kohei, Horaguchi, Ryusuke, Fujihira, Takuma, Nabe, Yoshimi, Minemura, Tomoki, Dang, Nam H, Sato, Tsutomu

“…A potential association between hematopoietic stem cell status in bone marrow and surrounding bone tissue has been hypothesized, and some studies have…”
Get full text

Humanized anti‐IL‐26 monoclonal antibody as a novel targeted therapy for chronic graft‐versus‐host disease by Hatano, Ryo, Itoh, Takumi, Otsuka, Haruna, Saeki, Harumi, Yamamoto, Ayako, Song, Dan, Shirakawa, Yuki, Iyama, Satoshi, Sato, Tsutomu, Iwao, Noriaki, Harada, Norihiro, Aune, Thomas M., Dang, Nam H., Kaneko, Yutaro, Yamada, Taketo, Morimoto, Chikao, Ohnuma, Kei

“…IL‐26 is a Th17 cytokine, with its gene being absent in rodents. To characterize the in vivo immunological effects of IL‐26 in chronic systemic inflammation,…”
Get full text

Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study by Hoppe, Bradford S., MD, MPH, Flampouri, Stella, PhD, Zaiden, Robert, MD, Slayton, William, MD, Sandler, Eric, MD, Ozdemir, Savas, MD, Dang, Nam H., MD, PhD, Lynch, James W., MD, Li, Zuofeng, DSc, Morris, Christopher G., MS, Mendenhall, Nancy P., MD

“…Purpose This study describes the early clinical outcomes of a prospective phase 2 study of consolidative involved-node proton therapy (INPT) as a component of…”
Get full text

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer by Shah, Chintan, Hong, Young-Rock, Bishnoi, Rohit, Ali, Azka, Skelton, 4th, William Paul, Dang, Long H, Huo, Jinhai, Dang, Nam H

“…Dipeptidyl peptidase-4 (DPP4), a cell surface protein, exhibits a crucial role in tumor biology and regulation of the immune system. We aim to study the impact…”
Get full text

CD9 negatively regulates CD26 expression and inhibits CD26-mediated enhancement of invasive potential of malignant mesothelioma cells by Okamoto, Toshihiro, Iwata, Satoshi, Yamazaki, Hiroto, Hatano, Ryo, Komiya, Eriko, Dang, Nam H, Ohnuma, Kei, Morimoto, Chikao

“…CD26/dipeptidyl peptidase IV is a cell surface glycoprotein which consists of multiple functional domains beside its ectopeptidase site. A growing body of…”
Get full text

DPP8 is a novel therapeutic target for multiple myeloma by Sato, Tsutomu, Tatekoshi, Ayumi, Takada, Kohichi, Iyama, Satoshi, Kamihara, Yusuke, Jawaid, Paras, Rehman, Mati Ur, Noguchi, Kyo, Kondo, Takashi, Kajikawa, Sayaka, Arita, Kotaro, Wada, Akinori, Murakami, Jun, Arai, Miho, Yasuda, Ichiro, Dang, Nam H., Hatano, Ryo, Iwao, Noriaki, Ohnuma, Kei, Morimoto, Chikao

“…Dipeptidyl peptidases (DPPs) are proteolytic enzymes that are ideal therapeutic targets in human diseases. Indeed, DPP4 inhibitors are widely used in clinical…”
Get full text

Tumor-to-tumor metastasis of diffuse large B cell lymphoma to gastric adenocarcinoma via CXCL12 (SDF-1)/CXCR4 axis: a case report by Kamihara, Yusuke, Murai, Sayaka, Kikuchi, Shohei, Wada, Akinori, Murakami, Jun, Dang, Nam H, Sato, Tsutomu

“…Abstract Background Tumor-to-tumor metastasis is the rare phenomenon in which one tumor exhibits metastatic deposits from another. To the best of our…”
Get full text

CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway by Hatano, Ryo, Ohnuma, Kei, Otsuka, Haruna, Komiya, Eriko, Taki, Izumi, Iwata, Satoshi, Dang, Nam H, Okumura, Ko, Morimoto, Chikao

“…CD26 is associated with T cell signal transduction processes as a costimulatory molecule, and CD26(+) T cells have been suggested to be involved in the…”
Get full text

Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy by Ohnuma, Kei, Hatano, Ryo, Dang, Nam H., Morimoto, Chikao

“…Immune checkpoint inhibitors (ICIs) have drastically altered cancer treatment paradigms, with increasing numbers of novel ICIs being currently evaluated in…”
Get full text

Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study by Bishnoi, Rohit, Hong, Young‐Rock, Shah, Chintan, Ali, Azka, Skelton, William P., Huo, Jinhai, Dang, Nam H., Dang, Long H.

“…Background Dipeptidyl peptidase 4 (DPP4) is a cell surface protein that can act as a tumor suppressor or activator, depending upon the level of expression and…”
Get full text

Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22 by Okamoto, Toshihiro, Yamazaki, Hiroto, Hatano, Ryo, Yamada, Taketo, Kaneko, Yutaro, Xu, C. Wilson, Dang, Nam H., Ohnuma, Kei, Morimoto, Chikao

“…Malignant pleural mesothelioma (MPM) is an aggressive malignancy arising from mesothelial lining of pleura. It is associated with a poor prognosis, partly due…”
Get full text

Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens by Hatano, Ryo, Yamada, Taketo, Madokoro, Hiroko, Otsuka, Haruna, Komiya, Eriko, Itoh, Takumi, Narita, Yuka, Iwata, Satoshi, Yamazaki, Hiroto, Matsuoka, Shuji, Dang, Nam H, Ohnuma, Kei, Morimoto, Chikao

“…A 110-kDa type II transmembrane glycoprotein with dipeptidyl peptidase IV (DPPIV) activity in its extracellular region, CD26 has a multitude of biological…”
Get full text

Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis by Hatano, Ryo, Itoh, Takumi, Otsuka, Haruna, Okamoto, Sayo, Komiya, Eriko, Iwata, Satoshi, Aune, Thomas M, Dang, Nam H, Kuwahara-Arai, Kyoko, Ohnuma, Kei, Morimoto, Chikao

“…Interleukin (IL)-26, known as a Th17 cytokine, acts on various cell types and has multiple biological functions. Although its precise role still remains to be…”
Get full text

Prevention of acute graft‐versus‐host disease by humanized anti‐CD26 monoclonal antibody by Hatano, Ryo, Ohnuma, Kei, Yamamoto, Junpei, Dang, Nam H., Yamada, Taketo, Morimoto, Chikao

“…Summary CD26 (DPP4) is a T cell costimulatory molecule as well as T cell activation marker, and CD26+ T cells are accumulated in inflamed tissues, such as…”
Get full text